Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?Zacks Investment Research • 12/05/19
Jounce Therapeutics, Inc. (JNCE) Shares March Higher, Can It Continue?Zacks Investment Research • 12/03/19
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/08/19
Jounce Therapeutics, Inc. (JNCE) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/07/19
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual MeetingGlobeNewsWire • 10/01/19
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate SecretaryGlobeNewsWire • 09/17/19
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19
Jounce's Newly Restructured Deal Is Still Bullish For Its Long-Term ProspectsSeeking Alpha • 08/01/19
Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings?Zacks Investment Research • 05/01/19